Onkologie
Gynäkologische Onkologie
Gynäkologie
Gynäkologische Onkologie
Termin
11.
-
13.05.2023
Themen
- Selecting biomarkers to inform neoadjuvant strategies
- Optimal treatment strategies in early breast cancer
- Targeted options for advanced luminal breast cancers
- HER2 and beyond: The role for antibody drug conjugates (ADCs) in HER2 non overexpressing breast cancers
- Refining checkpoint inhibition in triple-negative breast cancer (TNBC)
- From familial to theranostic germline genetics in breast cancer
- Micrometastatic node positive disease should be considered as node-negative for systemic treatment decisions
- Optimal sequencing in advanced luminal breast cancer
- New comers in the early breast cancer setting: Checkpoint and PARP inhibitors
- Novel endocrine therapies
- Utility of real-world data
- Special considerations in young breast cancer patients
- Keynote lecture -The future of early cancer detection
- New algorithms for HER2 positive breast cancer
- Post neoadjuvant local treatment in 2023
- ctDNA monitoring in early and advanced breast cancer
- Precision/personalised breast cancer medicine: Where do we stand
- Beyond breast cancer: Survivorship
Veranstaltungsart
Hybrid
Ort
Hub27 - Messe Berlin
Jafféstraße 2
14055 Berlin
Wissenschaftliche Leitungen
Prof. Dr. Suzette Delaloge
Prof. Sung-Bae Kim
Dr. Erika Hamilton
Fortbildungspunkte (CME)
beantragt
Veranstalter
European Society for Medical Oncology (ESMO)
Via Ginevra 4
6900 Lugano (CH)
Tel.: +41 919731963
Fax: +41 919731918
Webseite der Veranstaltung